Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sodium MRI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    176 result(s) found for: Sodium MRI. Displaying page 5 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2008-003016-35 Sponsor Protocol Number: CLBH589E2214 Start Date*: 2008-10-07
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio Fase II de Panobinostat oral, en pacientes adultos con Linfoma de Hodgkin clásico refractario/en recaida, después de fallo a dosis altas de quimioterapia con transfusión autóloga de células...
    Medical condition: Linfoma de Hodgkin clásico refractario/en recaída
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004130-25 Sponsor Protocol Number: DUR001-304 Start Date*: 2016-03-07
    Sponsor Name:Durata Therapeutic International B.V.
    Full Title: A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteom...
    Medical condition: Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005720-15 Sponsor Protocol Number: CLZC696A2224 Start Date*: 2013-09-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hyperten...
    Medical condition: Hypertensive patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002204-33 Sponsor Protocol Number: C32322 Start Date*: 2007-03-02
    Sponsor Name:UCB Pharma S.A.
    Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose...
    Medical condition: Relapsing forms of multiple slerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002721-99 Sponsor Protocol Number: CT114-2022-01 Start Date*: 2023-03-28
    Sponsor Name:Klinikum Nürnberg
    Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou...
    Medical condition: Stage 3 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005057-87 Sponsor Protocol Number: 337HNAS21016 Start Date*: 2022-06-15
    Sponsor Name:Inventiva S.A.
    Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin...
    Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000203-82 Sponsor Protocol Number: SHP626-201 Start Date*: 2016-11-09
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter...
    Medical condition: Nonalcoholic steatohepatitis (NASH), is a clinical condition occurring in individuals who do not drink excessive alcohol (>20 grams/day), yet have hepatic histology which is indistinguishable from ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002824-42 Sponsor Protocol Number: SPIRI-201 Start Date*: 2012-04-17
    Sponsor Name:Stealth Peptides Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia™ (MTP-131) on Reperfusion Injury in Patients Treated with St...
    Medical condition: Reperfusion injury in ST-segment Elevation Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-002538-14 Sponsor Protocol Number: 218672 Start Date*: 2023-06-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: 17-beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004709-24 Sponsor Protocol Number: CERL080ANL05 Start Date*: 2007-03-20
    Sponsor Name:ErasmusMC
    Full Title: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011516-37 Sponsor Protocol Number: 14022009 Start Date*: 2009-05-29
    Sponsor Name:Danish Multiple Sclerosis Research Centre
    Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl...
    Medical condition: Multiple Sclerosis, with primary and secondary progressive courses.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002628-34 Sponsor Protocol Number: thorp8617-1 Start Date*: 2012-08-29
    Sponsor Name:Thor Petersen
    Full Title: Optic neuritis and early treatment with methylprednisolone.
    Medical condition: Optic neuritis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10030946 Optic neuritis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001683-37 Sponsor Protocol Number: 2018012805 Start Date*: 2018-07-03
    Sponsor Name:Rigshospitalet
    Full Title: The RIME-IVF study Investigation of RIsk factors in out-of-hospital-cardiac-arrest patients, and MEdical treatment in Idiopathic Ventricular Fibrillation patients
    Medical condition: Unexplained cardiac arrest patients after thorough investigations (Idiopathic ventricular fibrillation, IVF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003522-25 Sponsor Protocol Number: APHP180672 Start Date*: 2020-02-28
    Sponsor Name:AP-HP
    Full Title:
    Medical condition: acute osteomyelitis of the child
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001494-23 Sponsor Protocol Number: RI-B-2021-7300-07 Start Date*: 2021-06-10
    Sponsor Name:Groupe Hospitalier Diaconesses-Croix-Saint-Simon
    Full Title: EFFICACY OF ROUTINE MANAGEMENT BY LOCAL ANAESTHETIC INFILTRATION IN THE TREATMENT OF PUDENDAL NEURALGIA: A RANDOMISED TRIAL AGAINST SALINE
    Medical condition: Patients with pudendal neuralgia who have failed drug treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000828-19 Sponsor Protocol Number: NN9535-4662 Start Date*: 2021-01-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003755-21 Sponsor Protocol Number: ISIS304801-CS7 Start Date*: 2016-06-06
    Sponsor Name:Akcea Therapeutics
    Full Title: An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    20.0 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000632-26 Sponsor Protocol Number: TMC-BIV-11-02 Start Date*: 2013-03-22
    Sponsor Name:The Medicines Company
    Full Title: Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3
    Medical condition: Patients undergoing transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000493-35 Sponsor Protocol Number: ISIS-304801-CS17 Start Date*: 2016-02-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy
    Medical condition: Partial lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001048-40 Sponsor Protocol Number: B1371013 Start Date*: 2015-02-10
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib.
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 21:48:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA